论文部分内容阅读
目的 检测NY- ESO -1和LAGE- 1癌症睾丸抗原在肝细胞癌中的表达,探讨其作为肝细胞癌免疫治疗靶标的可行性及其与肝癌生物学行为的关系。方法 逆转录聚合酶链反应(RT -PCR)和免疫组织化学EnVision二步法检测30例肝细胞癌新鲜标本NY ESO -1和LAGE -1的表达;另将191例肝癌石蜡组织制成芯片观察NY- ESO- 1蛋白在肝癌中的分布和表达。结果NY- ESO -1和LAGE -1基因mRNA在肝癌中的阳性表达率分别是33. 3% (10 /30)和16. 7% (5 /30),至少表达1种基因mRNA者为36 7% (11 /30);NY- ESO -1蛋白主要分布在肝癌细胞胞质,有效标本中NY ESO 1表达13 8% (24 /174),小肝癌、中晚期肝癌、发生转移肝癌中的阳性表达率逐渐升高,分别为6 8% (3 /44)、16 2% (21 /130)、23 1% (12 /52),不发生转移的肝癌仅为9 8% ( 12 /122 ),其中转移组与无转移组之间比较差异有统计学意义(P<0 .05),全部病例癌组织与癌旁组织比较差异有统计学意义(P<0 .01)。NY- ESO-1蛋白的阳性表达与肿瘤大小无关,所有癌旁肝组织均未见NY -ESO -1和LAGE -1的mRNA和蛋白的表达。结论 NY -ESO- 1 /LAGE- 1在肝细胞癌组织中的特异性表达提示其可作为肝细胞癌特异性免疫治疗潜在的靶标;NY -ESO -1在肝癌早期出现,随病情进展表达率逐步增高,转移患者最高,提示N
Objective To detect the expression of NY-ESO-1 and LAGE-1 cancer testis antigens in hepatocellular carcinoma (HCC) and to explore their feasibility as target of hepatocellular carcinoma immunotherapy and their relationship with the biological behavior of HCC. Methods Reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry EnVision two-step method were used to detect the expression of NY ESO-1 and LAGE-1 in 30 specimens of hepatocellular carcinoma. The distribution and expression of NY-ESO-1 protein in hepatocellular carcinoma. Results The positive expression rates of NY-ESO-1 and LAGE-1 mRNA in hepatocellular carcinoma were 33.3% (10/30) and 16.7% (5/30), respectively. The mRNA expression of at least one gene was 36 NYO-ESO-1 protein mainly distributed in the cytoplasm of hepatoma cells, and NY ESO 1 expression in effective samples was 13 8% (24/174), small hepatocellular carcinoma, advanced hepatocellular carcinoma, and metastatic hepatocellular carcinoma The positive expression rate of HCC was 68% (3/44), 16 2% (21/130), 23 1% (12/52) respectively, and only 9 8% (12/122) ), And there was significant difference between metastasis group and non-metastasis group (P <0.05). There was significant difference between all cases and adjacent non-cancerous tissues (P <0.01). The positive expression of NY-ESO-1 protein was not related to the tumor size. No mRNA and protein expressions of NY-ESO-1 and LAGE-1 were found in all the adjacent liver tissues. Conclusion The specific expression of NY-ESO-1 / LAGE-1 in hepatocellular carcinoma suggests that it may serve as a potential target for hepatocellular carcinoma-specific immunotherapy. NY-ESO-1 appears early in hepatocellular carcinoma, Gradually increased, the highest transfer patients, suggesting N